Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
US7097970B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2001 |
| Grant date | Aug 29, 2006 |
| Priority date | — |
| Expiry date | Jun 4, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/502
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.